Strategic licensing Opportunity exists in leveraging Statera's TLR5 agonist platform, including entolimod for ARS, through partnerships or licensing arrangements similar to the Tivic Health deal, to accelerate co-development or commercialization with adjacent biotech and government-related programs.

Recovery from setbacks Note recent leadership transition and past bankruptcy exposure; position sales outreach to highlight experienced advisory support, potential strategic realignment, and risk-mitigated partnerships to reassure investors and potential licensees about governance and program continuity.

Clinical asset leverage Statera’s entolimod program represents a clinically interesting asset with regulatory history; potential customers include government health programs, national labs, and biotech firms seeking radioprotection or mitigation indications, suggesting targeted outreach to public sector and defense-related health entities.

Collaborative potential Past and present partnerships with Coeptis, Worksite Labs, and Holobeam indicate openness to collaboration; pursue co-development, CRO, or testing collaborations that align with their diagnostic and regulatory capabilities to broaden exposure and de-risk partnerships.

Financial signal Revenue range and substantial funding indicate staying power; approach investors and strategic buyers with a narrative around scalable licensing, milestone-driven revenue, and potential upsell opportunities through additional indications or expanded rights across regions.